/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Emmaus Life Sciences (EMMA) generated about $12 million in revenue and -$8 million in net income (a -70.6% net margin) over the trailing twelve months, growing at roughly -11.7% a year. Figures are from SEC filings; this is analysis, not investment advice.
Emmaus Life Sciences generated about $12 million in revenue over the trailing twelve months. Revenue has grown at roughly -11.7% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Emmaus Life Sciences reported about -$8 million in net loss over the trailing twelve months, a net margin of roughly -70.6%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Emmaus Life Sciences runs a gross margin of about 93.3%, an operating margin of about 3.2%, a net margin of about -70.6%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Emmaus Life Sciences's revenue has compounded at roughly -11.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside EMMA's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 15 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 24 Jun 2026. How this is calculated.
Fiscal year ends Dec.